Pancreatic Cancer Research

ResearcherThe University of Texas MD Anderson Cancer CenterActive in the last 2 years

Giulio Francesco Draetta

ORCID-verified (high confidence, 0.95), identity_conf@1As of 6 November 2026

Matched on ORCID iD 0000-0001-5225-9610; OpenAlex author ID A5037541103. Sources: funder_awards.

Their work

Papers
20 (first author 0, last author 10)
Trials
0
Grants
2
Labs led
1
Collaborators
60
Papers, trials and grants by year

2014: 2 papers, 1 grant · 2015: 1 paper · 2016: 1 paper · 2017: 2 papers, 1 grant · 2018: none · 2019: 3 papers · 2020: 1 paper · 2021: 1 paper · 2022: none · 2023: none · 2024: 3 papers · 2025: none · 2026: 6 papers

Papers 20

  1. Syndecan-1-targeted therapeutic antibody impairs macropinocytosis and elicits antitumor immunity in pancreatic cancer. Co-author DOI 10.1016/j.xcrm.2026.102613↗
  2. Author Correction: Oncogene ablation-resistant pancreatic cancer cells depend on mitochondrial function. Last author DOI 10.1038/s41586-026-10488-6↗
  3. Author Correction: Synthetic vulnerabilities of mesenchymal subpopulations in pancreatic cancer. Co-author DOI 10.1038/s41586-026-10995-6↗
  4. Author Correction: Genomic deletion of malic enzyme 2 confers collateral lethality in pancreatic cancer. Co-author DOI 10.1038/s41586-026-11134-x↗
  5. GFER Represents a Target for Dual Disruption of Redox Homeostasis and Reactivation of the Immune Response in Pancreatic Adenocarcinoma. Last author DOI 10.1158/0008-5472.can-24-4211↗
  6. DPY30 Is an Epigenetic Decoupler Linking Replication Stress to Immunoediting in Pancreatic Cancer. Last author DOI 10.1158/0008-5472.can-25-3849↗
  7. The KRAS mutational spectrum and its clinical implications in pancreatic cancer. Last author DOI 10.1016/j.ccell.2024.08.001↗
  8. WRAD core perturbation impairs DNA replication fidelity promoting immunoediting in pancreatic cancer Last author DOI 10.1101/2024.10.21.619543↗
  9. Clonal dominance defines metastatic dissemination in pancreatic cancer. Co-author DOI 10.1126/sciadv.add9342↗
  10. PRMT1-dependent regulation of RNA metabolism and DNA damage response sustains pancreatic ductal adenocarcinoma. Co-author DOI 10.1038/s41467-021-24798-y↗
  11. Diversity Across the Pancreatic Ductal Adenocarcinoma Disease Spectrum Revealed by Network-Anchored Functional Genomics Last author DOI 10.1101/2020.09.17.302034↗
  12. Syndecan 1 is a critical mediator of macropinocytosis in pancreatic cancer. Last author DOI 10.1038/s41586-019-1062-1↗
  13. Predictive Signatures Inform the Effective Repurposing of Decitabine to Treat KRAS-Dependent Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1158/0008-5472.can-19-0187↗
  14. YAP1 oncogene is a context-specific driver for pancreatic ductal adenocarcinoma. Co-author DOI 10.1172/jci.insight.130811↗
  15. Genomic deletion of malic enzyme 2 confers collateral lethality in pancreatic cancer. Co-author DOI 10.1038/nature21052↗
  16. Synthetic vulnerabilities of mesenchymal subpopulations in pancreatic cancer. Co-author DOI 10.1038/nature21064↗
  17. In Vivo Functional Platform Targeting Patient-Derived Xenografts Identifies WDR5-Myc Association as a Critical Determinant of Pancreatic Cancer. Last author DOI 10.1016/j.celrep.2016.05.063↗
  18. Genetic events that limit the efficacy of MEK and RTK inhibitor therapies in a mouse model of KRAS-driven pancreatic cancer. Last author DOI 10.1158/0008-5472.can-14-1854↗
  19. Yap1 activation enables bypass of oncogenic Kras addiction in pancreatic cancer. Co-author DOI 10.1016/j.cell.2014.06.003↗
  20. Oncogene ablation-resistant pancreatic cancer cells depend on mitochondrial function. Last author DOI 10.1038/nature13611↗

Grants 2

  1. Therapeutic Vulnerabilities of Mesenchymal Pancreatic Cancer Cells AWARD pancan:2017-giulio-draetta-md-phd-therapeutic-vulnerabilities-of-mesenchym
  2. Developing a novel oxidative phosphorylation inhibitor in pancreatic cancer AWARD pancan:2014-giulio-draetta-md-phd-developing-a-novel-oxidative-phosphoryla

Closest collaborators

The 25 strongest of 60 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Giannicola Genovese · 15 shared papers, 2014–2026 · strength 1.97
  2. Andrea Viale · 16 shared papers, 2014–2026 · strength 1.70
  3. Haoqiang Ying · 14 shared papers, 2014–2026 · strength 1.56
  4. Timothy Paul Heffernan · 15 shared papers, 2014–2026 · strength 1.52
  5. Huamin Wang · 13 shared papers, 2014–2026 · strength 1.34
  6. Wantong Yao · 12 shared papers, 2014–2026 · strength 1.28
  7. Alessandro Carugo · 13 shared papers, 2014–2026 · strength 1.27
  8. Jason B. Fleming · 12 shared papers, 2014–2026 · strength 1.07
  9. Virginia Giuliani · 9 shared papers, 2014–2026 · strength 1.03
  10. Anirban Maitra · 10 shared papers, 2016–2026 · strength 0.95
  11. Ronald Anthony Depinho · 10 shared papers, 2014–2026 · strength 0.88
  12. I-Lin Ho · 6 shared papers, 2019–2026 · strength 0.80
  13. Ziheng Chen · 5 shared papers, 2019–2026 · strength 0.72
  14. Luigi Perelli · 3 shared papers, 2024–2026 · strength 0.67
  15. Ya’an Kang · 7 shared papers, 2014–2026 · strength 0.67
  16. Francesca Citron · 4 shared papers, 2024–2026 · strength 0.66
  17. Prasenjit Dey · 4 shared papers, 2017–2026 · strength 0.49
  18. Tony Gutschner · 4 shared papers, 2017–2026 · strength 0.49
  19. Johnathon Lynn Rose · 5 shared papers, 2016–2026 · strength 0.47
  20. Michael P. Kim · 5 shared papers, 2019–2024 · strength 0.44
  21. Piergiorgio Pettazzoni · 7 shared papers, 2014–2026 · strength 0.43
  22. Avnish Kapoor · 5 shared papers, 2014–2026 · strength 0.35
  23. Lynda Chin · 4 shared papers, 2014–2026 · strength 0.29
  24. Lifeng Yang · 2 shared papers, 2017–2026 · strength 0.26
  25. Di Zhao · 2 shared papers, 2017–2026 · strength 0.26

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.